Estragen Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 16 Year, 25 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.00 M
- Revenue Growth 25.62%
- Profit Growth 56.29%
- Ebitda 297.32%
- Net Worth 27.02%
- Total Assets 25.98%
About Estragen Pharma
Estragen Pharma Private Limited (EPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 29 January 2009 and has a history of 16 years. Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Shyam Gurhani and Manju Gurhani serve as directors at the Company.
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24232RJ2009PTC028192
- Company No.
028192
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jan 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Estragen Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shyam Gurhani  | Director | 29-Jan-2009 | Current |
| Manju Gurhani | Director | 29-Jan-2009 | Current |
Financial Performance of Estragen Pharma.
Estragen Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 25.62% increase. The company also saw a substantial improvement in profitability, with a 56.29% increase in profit. The company's net worth Soared by an impressive increase of 27.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Estragen Pharma?
In 2020, Estragen Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹5.00 M
Charges Breakdown by Lending Institutions
- Others : 0.30 Cr
- Icici Bank Limited : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Dec 2017 | Others | ₹3.00 M | Satisfied |
| 16 Dec 2013 | Icici Bank Limited | ₹2.00 M | Satisfied |
How Many Employees Work at Estragen Pharma?
Estragen Pharma has a workforce of 23 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Estragen Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Estragen Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.